Form 4: Crinetics Pharmaceuticals Executive James Hassard Reports Stock and Option Transactions
SEC Form 4 Filing
Chief Commercial Officer James Hassard reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.
Summary
- On March 4, 2024, James Hassard, Chief Commercial Officer of Crinetics Pharmaceuticals, reported transactions involving the company's stock.
- Hassard acquired 17,000 shares of common stock as restricted stock units at $0.00, with 25% vesting annually starting March 15, 2025.
- He also acquired options to purchase 63,000 shares of common stock at an exercise price of $43.51, vesting monthly over four years from March 4, 2024.
- Following these transactions, Hassard directly owns 31,000 shares of Crinetics Pharmaceuticals.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a standard practice and indicates confidence in the company's future, but it's not overwhelmingly positive.
Positives
- The acquisition of restricted stock units and stock options suggests confidence in the company's future performance from a key executive.
Future Outlook
The vesting schedules for both the restricted stock units and stock options indicate a long-term incentive structure for the executive.
Industry Context
Executive compensation through stock options and restricted stock units is a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize long-term growth.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
- Vesting schedules, such as the four-year monthly vesting for the options and annual vesting for the restricted stock units, are typical to encourage long-term commitment.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align executive interests with long-term company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of transaction: acquisition of restricted stock units and stock options. |
| 03/04/2024 | Vesting commencement date for stock options. |
| 03/15/2025 | First vesting date for restricted stock units (25%). |
| 03/03/2034 | Expiration date for stock options. |
| 03/06/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.